Publikationen in Zusammenarbeit mit Forschern von Complejo Asistencial Universitario de Burgos (24)

2022

  1. Novel Therapies to Address Unmet Needs in ITP

    Pharmaceuticals, Vol. 15, Núm. 7

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain

    British Journal of Haematology, Vol. 194, Núm. 3, pp. 537-541

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Identification of 58 mutations (26 Novel) in 94 of 109 symptomatic Spanish probands with protein C deficiency

    Thrombosis and Haemostasis, Vol. 119, Núm. 9, pp. 1409-1418

  3. Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group

    Advances in Hematology, Vol. 2019

  4. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content

    Platelets, Vol. 30, Núm. 6, pp. 743-751

2017

  1. Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes

    Thrombosis and Haemostasis, Vol. 117, Núm. 1, pp. 66-74

  2. Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®

    Quality of Life Research, Vol. 26, Núm. 3, pp. 767-778

  3. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

    International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516

  4. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970

2016

  1. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

  2. Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk

    Cardiovascular Research, Vol. 110, Núm. 3, pp. 309-318

  3. Influence of UGT2B7, CYP3A4, and OPRM1 Gene Polymorphisms on Transdermal Buprenorphine Pain Control in Patients with Critical Lower Limb Ischemia Awaiting Revascularization

    Pain Practice, Vol. 16, Núm. 7, pp. 842-849

  4. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center

    Thrombosis Research, Vol. 142, pp. 52-56

  5. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines

    Annals of Hematology, Vol. 95, Núm. 7, pp. 1089-1098

2015

  1. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

  2. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

  3. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia

    Platelets, Vol. 26, Núm. 1, pp. 83-86